SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-0.42%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$388M
AUM Growth
+$388M
(-13%)
Cap. Flow
-$52.3M
Cap. Flow
% of AUM
-13.47%
Top 10 Holdings %
Top 10 Hldgs %
66.6%
Holding
38
New
1
Increased
13
Reduced
15
Closed
7
Top Buys
| 1 |
Baxter International
BAX
|
$9.1M |
| 2 |
Elevance Health
ELV
|
$5.33M |
| 3 |
Biogen
BIIB
|
$4.73M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.64M |
| 5 |
Zimmer Biomet
ZBH
|
$3.17M |
Top Sells
| 1 |
Merck
MRK
|
$13.9M |
| 2 |
Organon & Co
OGN
|
$12M |
| 3 |
CVS Health
CVS
|
$11.9M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$9.43M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.19M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.89M | 0.49% |
45,520
-701
| -2% | -$29K |
|
27
Vir Biotechnology
VIR
$686M
| $1.73M | 0.45% |
89,808
-20,415
| -19% | -$393K |
|
28
Rigel Pharmaceuticals
RIGL
$697M
| $1.59M | 0.41% |
1,346,904
-119,774
| -8% | -$141K |
|
|
29
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.39M | 0.36% |
6,921
-35,923
| -84% | -$7.19M |
|
30
Novavax
NVAX
$1.21B
| $1.03M | 0.27% |
56,735
+1,411
| +3% | +$25.7K |
|
31
Embecta
EMBC
$847M
| $151K | 0.04% |
5,246
| – | – |
|
32
Abbott
ABT
$231B
| – | – |
-49,205
| Closed | -$5.35M |
|
33
Atara Biotherapeutics
ATRA
$84.6M
| – | – |
-123,713
| Closed | -$964K |
|
|
34
Organon & Co
OGN
$2.45B
| – | – |
-356,089
| Closed | -$12M |
|
35
Pfizer
PFE
$141B
| – | – |
-100,000
| Closed | -$5.24M |
|
|
SLGC
36
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| – | – |
-301,224
| Closed | -$1.36M |
|
37
Quanterix
QTRX
$211M
| – | – |
-88,670
| Closed | -$1.44M |
|
|
38
Vertex Pharmaceuticals
VRTX
$100B
| – | – |
-33,474
| Closed | -$9.43M |
|